粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究

打开文本图片集

【中图分类号】R735.3【文献标志码】A【收稿日期】2024-09-14

【AbstractObjective：Toinvestigatetheclinicalperformanceoffecalsyndecan2（SDC2）/issuefactorpathwayinhibitor2（FPl2） genemethylationassayinprospectivecolorectalcancerscreenig.Methods：Theindividualswhounderwentoutinephysicaleainationwereenroledassubjects，andtheirfecalsamples werecolectedandtestedwithfecal SDC2/P2gene methylationasyIn addition，enteroscopywasrecommendedforthesubjects withpositiveresults.Results：Atotalof15subjectsreceivedfecalSDC2/ TFPI2 gene methylation assay，among whom there were 7O8 male subjects and 507 female subjects，with a mean age of （44.7±13.9 ） years.Among all subjects，28 had positive test results，resulting in apositive rate of 2.30% ，and among these 28 subjects， 27（96.43% ） underwent enteroscopy，among whom 16（59.26 % ）had abnormal findings.With enteroscopy and/or pathological examination as diagnostic criteria，fecal SDC2/TFPI2 gene methylation assay had a positive predictive value of 7.41% for colorectal cancer， 22.22% for progressive precancerous lesion，and 7.41% for non-progressive precancerous lesion. Conclusion： Fecal SDC2/TFPI2 gene methylationassayshowsgoodclinical performance inprospectivecolorectalcancerscreeningandthusprovidesanoninvasive methodforthe screening and auxiliary diagnosis of colorectal cancer.

【Key words】syndecan 2;tissue factor pathway inhibitor 2;methylation;colorectal cancer;screening

根据全球癌症统计报告2020的数据，结直肠癌的发病率在所有恶性肿瘤中居于第3位，是癌症相关死亡的第二大原因]。（剩余9508字）